Safety Tolerability footer references
References 1. Data on File, 309560. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 2. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with
fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer [published errata
appears in
J Clin Oncol.
2011;29(16):2293]
J Clin Oncol
. 2010;28(30):4594-4600. 3. FASLODEX [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2010.
Recent Videos
Related Content
Elevating the Quality of Cancer Care via Cross-Department Collaboration
Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025Podcast
Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
